Akari Therapeutics Plc Sponsored ADR Stock

$1.16

0.93% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US00972G1085

Symbol

AKTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Akari Therapeutics Plc Sponsored ADR Stock price

$1.16

-44.04 97.44% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.01 0.93%

ISIN

US00972G1085

Symbol

AKTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$33.8m

Enterprise Value

$34.5m

Net debt

$660.0k

Cash

$2.6m

Shares outstanding

Valuation (TTM | estimate)

P/E

- | negative

P/S

- | 7.90

EV/Sales

- | 8.05

EV/FCF

negative

P/B

Financial Health

Equity Ratio

43.96%

Return on Equity

-89.03%

ROCE

-57.72%

ROIC

Debt/Equity

0.15

Financials (TTM | estimate)

Revenue

$0.0 | $4.3m

EBITDA

$-17.7m | -

EBIT

$-17.7m

Net Income

$-19.8m | -

Free Cash Flow

$-12.6m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

32.03% | -

EBIT

32.00%

Net Income

-52.11% | -

Free Cash Flow

23.62%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$0.00

FCF per Share

Short interest

0.16%

Employees

9.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Akari Therapeutics Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Akari Therapeutics Plc Sponsored ADR forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Akari Therapeutics Plc Sponsored ADR forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Akari Therapeutics Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	11 11	38% 38% -
- Research and Development Expense	6.98 6.98	20% 20% -
EBITDA	-18 -18	32% 32% -
- Depreciation and Amortization	0.01 0.01	- -
EBIT (Operating Income) EBIT	-18 -18	32% 32% -
Net Profit	-20 -20	52% 52% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Akari Therapeutics Plc Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

3 days ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Access the “What This Means” segment here BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced it recently participated in a Virtual Investor “What This Means” segment. For the segment, Abizer Gaslightwala...

Neutral

GlobeNewsWire

●

10 days ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms

Neutral

GlobeNewsWire

●

30 days ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates

More Akari Therapeutics Plc Sponsored ADR News

Company Profile

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Abizer Gaslightwala
Employees	9
Founded	2004
Website	www.akaritx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now